—
C+
C+ The full Closelooknet — membership. Open the C+ overview

Caris Life Sciences, Inc. Common Stock（CAI）— 同業公司組

數據截至2026-10-07 — 評分每個交易日晚間重新計算。分組標準＝首先為共同的Closelook指數成分，其次為產業。Closelook研究日記，不構成投資建議。

Caris Life Sciences, Inc. Common Stock的Closelook綜合評分為59/100，在同業公司組內排名第5位（共7家）——組內評分最高的是BB Biotech AG（74/100）。

名稱綜合動能品質估值訊號距52週高點
CAI Caris Life Sciences, Inc. Common Stock59796226ok19.5%
BION.SW BB Biotech AG74639681info12.3%
ONC BeiGene, Ltd.64816532ok5.5%
PTGX Protagonist Therapeutics Inc60776212info12.4%
REGN Regeneron Pharmaceuticals Inc60607252watch14%
CORT Corcept Therapeutics Incorporated57965024ok5.4%
TGTX TG Therapeutics Inc54706829info10.7%

評分為Closelook全部涵蓋範圍內的相對讀數——方法論詳見公司評分說明。訊號燈來自每日夜間訊號看板。

FAQ · from the current data · as of 2026-10-07

Quick answers

Caris Life Sciences, Inc. Common Stock在Closelook涵蓋範圍內的同業公司有哪些？

分組首先根據共同的Closelook指數成分，其次根據產業：BB Biotech AG (BION.SW)、BeiGene, Ltd. (ONC)、Protagonist Therapeutics Inc (PTGX)、Regeneron Pharmaceuticals Inc (REGN)、Corcept Therapeutics Incorporated (CORT)、TG Therapeutics Inc (TGTX)。

CAI相對同業公司的評分如何？

Caris Life Sciences, Inc. Common Stock的綜合評分為59/100，組內排名第5位（共7家），截至2026-10-07；組內最高綜合評分為BB Biotech AG（74/100）。Closelook評分為研究日記讀數，不構成評等或投資建議。

Related in the Closelooknet universe

then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.